USPTO serial 79333375
JOONGKYEOM ANTIBODY THERAPY
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Apr 4, 2023
- Examiner
- CHANG, ELIZABETH YI HSUAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with JOONGKYEOM ANTIBODY THERAPY?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ziwen Zhu
Ziwen Zhu Locke Lord LLPChurch Street P.O. Box 1470New York, NY 10008-1470UNITED STATESGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Preparations of microorganisms for medical use; bacterial preparations for medical and veterinary use; diagnostic preparations for medical and veterinary use; cultures of microorganisms for medical and veterinary use; preparations of microorganisms for medical and veterinary use; bacteriological preparations for medical and veterinary use; biological preparations for medical purposes; diagnostic agents for medical use; medicinal diagnostic reagents; pharmaceutical preparations for diagnosis; preparations for diagnosing antibodies; pharmaceutical preparations for the treatment of antibodies | ACTIVE | — |
| 035 | Wholesale store services featuring microorganisms for medical purposes; retail store services featuring microorganisms for medical purposes; wholesale store services featuring bacterial preparations for medical and veterinary use; retail store services featuring bacterial preparations for medical and veterinary use; wholesale store services featuring diagnostic preparations for medical and veterinary use; retail store services featuring diagnostic preparations for medical and veterinary use; business intermediary services relating to the matching of parties for purchase and sale of drugs for medical purposes; wholesale store services featuring drugs for medical purposes; retail store services featuring drugs for medical purposes; wholesale store services featuring medical preparations for diagnosing antibodies; retail store services featuring medical preparations for diagnosing antibodies; wholesale store services featuring medicinal diagnostic reagents; retail store services featuring medicinal diagnostic reagents; business intermediary services relating to the matching of parties for purchase and sale of medicinal diagnostic reagents; wholesale store services featuring pharmaceutical preparations for diagnosis; retail store services featuring pharmaceutical preparations for diagnosis; business merchandising display services; wholesale store services featuring pharmaceutical preparations for the treatment of antibodies; retail store services featuring pharmaceutical preparations for the treatment of antibodies; sales agency services, namely, independent sale representatives for pharmaceutical preparations for the treatment of antibodies | ACTIVE | — |
| 042 | Research and development of vaccines and medicines; advisory services relating to biotechnology; research relating to biotechnology; consulting services in the fields of biotechnology; biological research; medical research in the field of crude drugs; biochemical analysis; biochemistry research services; research on adult diseases; research relating to bacteriology; research services in the fields of cancerous diseases; development of pharmaceuticals; research relating to pharmaceuticals; advisory services relating to development of pharmaceuticals; pharmaceutical products evaluation; consultancy pertaining to pharmacology; research in the field of gene analysis; genetic research; research relating to medical products; medical research services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by JOONGKYEOM Co., Ltd.
- Other trademarks owned by JOONGKYEOM Co., Ltd.
- Other trademarks owned by JOONGKYEOM Co., Ltd.
- Other trademarks in Class 005
- Other trademarks in Class 035
- Other trademarks in Class 042
- Similar marks named JOONGKYEOM ANTIBODY THERAPY
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 11, 2024 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Aug 14, 2023 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jul 24, 2023 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jul 24, 2023 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Jul 4, 2023 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Apr 4, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Apr 4, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Jan 25, 2023 | GPNX | NOTIFICATION PROCESSED BY IB | — |
| Jan 17, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 17, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 4, 2023 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 4, 2023 | OP2R | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB | — |
| Dec 28, 2022 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 15, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Dec 14, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Dec 13, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Dec 13, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Nov 14, 2022 | RFNP | REFUSAL PROCESSED BY IB | — |
| Oct 22, 2022 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 21, 2022 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Aug 31, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 30, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 30, 2022 | RFWR | NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW | — |
| Aug 28, 2022 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Aug 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Aug 27, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Feb 19, 2022 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 15, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 10, 2022 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |